Horizon 2020 - Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial

Horizon 2020 - Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial
HIPGEN is a project funded by European Union within Horizon 2020 program for the research and innovation in terms of customized medicine. 
The aim of HIPGEN project  is to develop the first cell therapy, in order to improve functional recovery after arthroplasty following hip fracture.  The HIPGEN project, through an advanced multicenter study, proposes the use of a therapeutic, cell product derived from human placenta (PLX-PAD) for muscle regeneration after injury and intervention.   In particular, aspects such as the improvement of muscle function, mobility and reduction of post-operative, inflammatory status in patients with hip fractures treated with PLX-PAD during arthroplasty surgery will be evaluated.    
HIPGEN partners include the university hospitals Charité in Berlin and Odense in Denmark, the university of Oxford, ICON in Dublin,  the International Osteoporosis Foundation (IOF) and the non-EU partner Pluristem in Israel. 

Eugenia Menni Research Centre of Fondazione Poliambulanza, with a strong experience in the study of the immunological properties of placenta cells, is constantly engaged in this European project by investigating the mechanisms through which PLX-PAD promote muscle regeneration by acting on patient's immune system cells.

Click here  to get more information on Horizon 2020-Hipgen.